06.02.2023 | Letter to the Editor
Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia
Erschienen in: Annals of Hematology | Ausgabe 4/2023
Einloggen, um Zugang zu erhalten